Product Description
Camostat is an orally bioavailable, synthetic serine protease inhibitor, with anti-inflammatory, antifibrotic, and potential antiviral activities. Upon oral administration, camostat and its metabolite 4-(4-guanidinobenzoyloxyl)phenyl acetic acid (FOY 251) inhibit the activities of a variety of proteases, including trypsin, kallikrein, thrombin and plasmin, and C1r- and C1 esterases. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Camostat)
Mechanisms of Action: SP Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Korea | Philippines
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: COVID-19
Phase 3: COVID-19|Severe Acute Respiratory Syndrome|Communicable Diseases
Phase 2: Severe Acute Respiratory Syndrome|COVID-19|Obesity|Communicable Diseases|Hypertension|Respiratory Tract Infections|Proteinuria|Kidney Diseases|Cystic Fibrosis
Phase 1: COVID-19|Healthy Volunteers|Communicable Diseases|Severe Acute Respiratory Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04652765 |
COMBO | P1 |
Terminated |
Severe Acute Respiratory Syndrome|COVID-19|Communicable Diseases |
2021-09-15 |
2023-10-07 |
Primary Endpoints|Treatments |
|
JapicCTI-205326 |
JapicCTI-205326 | P1 |
Unknown |
COVID-19 |
2020-08-31 |
|||
NCT04451083 |
FOY-305-02 | P1 |
Completed |
Healthy Volunteers |
2020-08-17 |
88% |
2021-06-17 |
Primary Endpoints |
2023-508516-34-00 |
2023-508516-34-00 | P2 |
Recruiting |
Kidney Diseases|Proteinuria |
2025-12-31 |
2025-05-02 |
Treatments |
|
NCT04625114 |
COV-AAT | P2 |
Terminated |
COVID-19 |
2022-07-12 |
2024-08-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04662086 |
COPPS-Master Protocol | P2 |
Completed |
COVID-19 |
2022-05-03 |
2023-03-30 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04321096 |
CamoCO-19 | P2 |
Completed |
Communicable Diseases|COVID-19 |
2022-01-31 |
2025-04-19 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04470544 |
RECOVER | P2 |
Completed |
Severe Acute Respiratory Syndrome |
2021-12-22 |
2024-11-13 |
||
NCT04681430 |
RES-Q-HR | P2 |
Completed |
Communicable Diseases|Respiratory Tract Infections|COVID-19 |
2021-10-29 |
2022-02-12 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04750759 |
NICCAM | P2 |
Terminated |
COVID-19 |
2021-10-29 |
30% |
2021-12-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2020-001200-42 |
2020-001200-42 | P2 |
Terminated |
COVID-19 |
2021-09-06 |
2022-03-13 |
Treatments |
|
2020-003475-18 |
COV-AAT | P2 |
Completed |
Severe Acute Respiratory Syndrome|COVID-19 |
2021-06-24 |
|||
NCT04530617 |
NCT04530617 | P2 |
Terminated |
Hypertension|Obesity|COVID-19 |
2021-06-10 |
2021-06-22 |
Primary Endpoints |
|
NCT04662073 |
COPPS | P2 |
Terminated |
COVID-19 |
2021-06-08 |
2022-12-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
2020-002233-15 |
2020-002233-15 | P2 |
Completed |
COVID-19 |
2021-05-26 |
2022-03-13 |
Treatments |
|
NCT04524663 |
COPS-2003 | P2 |
Completed |
COVID-19 |
2021-05-15 |
2022-06-11 |
Patient Enrollment|Primary Endpoints |
|
NCT04374019 |
MCC-20-COVID-01-PMC | P2 |
Terminated |
COVID-19 |
2020-12-21 |
2022-01-21 |
||
NCT00506792 |
CQAU145A2201 | P2 |
Completed |
Cystic Fibrosis |
2008-12-01 |
2019-03-21 |
||
NCT04730206 |
DAWN | P3 |
Terminated |
Severe Acute Respiratory Syndrome|COVID-19 |
2022-07-13 |
2022-10-06 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2020-002110-41 |
SPIKE-1 | P3 |
Unknown status |
COVID-19 |
2022-06-18 |
2022-03-13 |
Treatments |
|
NCT04657497 |
FOY-305-01 | P3 |
Completed |
Communicable Diseases|COVID-19 |
2021-03-26 |
16% |
2021-06-15 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2020-003366-39 |
2020-003366-39 | P3 |
Active, not recruiting |
COVID-19 |
None |
2022-03-13 |
Treatments |
|
NCT04338906 |
CLOCC | P4 |
Withdrawn |
COVID-19 |
2021-12-01 |
2023-02-18 |
Primary Endpoints|Treatments |